Peptide A–Z Registry
Every compound, graded on what the evidence can actually carry
Most compounds in this section share a pattern: interesting biology, enthusiastic marketing, and a human evidence base far thinner than the confidence surrounding it. Filter by how strong the evidence really is.
Start with a compound
Direct links to frequently researched profiles, followed by the complete searchable directory below.
Retatrutide
An investigational GIP/GLP-1/glucagon triple agonist with positive pivotal Phase 3 results and no approval anywhere.
Tirzepatide
A dual GIP and GLP-1 receptor agonist with strong Phase 3 weight and glycaemic data.
BPC-157
The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.
Mostly animal and lab studies — not yet shown in people
TB-500 / Thymosin beta-4
A genuine biological protein with real research history, and a separate online product that is not quite the same thing.
Mostly animal and lab studies — not yet shown in people
MOTS-c
A mitochondrial-derived peptide with genuinely interesting biology and thin translational data.
Mostly animal and lab studies — not yet shown in people
SS-31 / Elamipretide
A mitochondria-targeting peptide with a narrow accelerated approval and a much broader set of unproven anti-ageing claims.
Category
Evidence level — strongest type of study
Evidence levels (L0-L5) describe research maturity, not safety or a recommendation. Human exposure reports and trial registration do not prove a claimed benefit; where they differ, claim-specific evidence is shown separately. Confidence and regulatory status are independent.
Regulatory status — legal and licensing position
Regulatory status is jurisdiction-, product-, formulation- and indication-specific. An approval in one country does not imply approval elsewhere or for every use. Regulatory status is separate from efficacy evidence, safety and recommendations.
Route — how it is given
Routes describe how a compound was given in the studies or approved product — for example injected under the skin, sprayed into the nose or taken by mouth. A route being sold or reported somewhere is not evidence it works or is safe that way.
Routes that were never approved are flagged as unapproved on each profile.
Abaloparatide
A PTHrP-based anabolic peptide for osteoporosis, with labelling extended to men at high fracture risk.
Afamelanotide
An approved melanocortin implant for a rare light-sensitivity disease — not a tanning drug, whatever the internet says.
AOD-9604
A growth-hormone fragment marketed for fat loss whose own obesity trials failed to establish a benefit.
Mostly animal and lab studies — not yet shown in people
Apitegromab
An investigational antibody that inhibits myostatin activation, with a peer-reviewed Phase 2 trial showing less DXA-measured lean-mass loss during tirzepatide treatment, but no proven functional outcome in obesity.
ARA-290
An 11-amino-acid EPO-derived peptide with real randomised human data in one narrow neuropathy setting.
ASC36
An investigational long-acting amylin receptor peptide agonist in Phase 1 studies for obesity, with no efficacy results in people.
ASC36_35FDC
A fixed-dose combination of two separate investigational peptides — amylin receptor agonist ASC36 and GLP-1/GIP agonist ASC35 — in Phase 1 for obesity.
AT-7687
An investigational peptide GIP receptor antagonist — it blocks the GIP receptor rather than activating it — in a Phase 2a study combined with semaglutide.
B7-33
A synthetic single-chain peptide derived from the relaxin-2 B-chain that signals at RXFP1; evidence is cell and animal work only.
Mostly animal and lab studies — not yet shown in people
BPC-157
The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.
Mostly animal and lab studies — not yet shown in people
Bremelanotide
An FDA-approved melanocortin agonist for one specific sexual-health diagnosis — endlessly mis-sold as a general performance enhancer.
Brenipatide
An investigational dual GIP and GLP-1 receptor agonist now in Phase 3 trials for alcohol use disorder and major depressive disorder, with no efficacy results published.
Bronchogen
A Khavinson-series tetrapeptide studied in a rat model of lung damage from nitrogen dioxide; no human study. Its reported sequence is inconsistent across sources.
Mostly animal and lab studies — not yet shown in people
Cagrilintide
A long-acting amylin analogue, now in its own Phase 3 programme as well as in combination therapy.
Calcitonin (salmon)
A salmon-derived hormone peptide once common in bone disease, now used more narrowly after regulators weighed modest benefit against a debated malignancy signal.
Carbetocin
A long-acting oxytocin analogue approved in many countries — but not the US — to prevent uterine atony after delivery.
Cardiogen
A Khavinson-series tetrapeptide tested on rat heart-tissue explants in a dish; not the CardioGen-82 heart-imaging agent, and not tested on living hearts.
Mostly animal and lab studies — not yet shown in people
Cartalax
A three-amino-acid Khavinson-series short peptide whose published evidence is cell-culture work, not human joint or cartilage outcomes.
Mostly animal and lab studies — not yet shown in people
CBL-514
An investigational localized fat-reduction small-molecule injection, studied for abdominal subcutaneous fat reduction rather than whole-body obesity treatment. Not a peptide.
Cetrorelix
The other widely used GnRH antagonist in assisted reproduction protocols.
CJC-1295
A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.
Degarelix
A GnRH antagonist approved for advanced prostate cancer — hormone suppression without the initial flare.
Desmopressin
A V2-selective vasopressin analogue approved in nasal, oral and injectable formulations — each tied to its own specific indications.
DSIP / Emideltide
A neuropeptide named for a sleep effect first described in the 1970s that decades of follow-up have never clearly replicated in humans.
Mostly animal and lab studies — not yet shown in people
Eloralintide
An investigational selective amylin-pathway agonist now in a broad Phase 3 programme.
EloraTZP
An experimental combination of the amylin receptor agonist eloralintide with tirzepatide, studied as a combination rather than a single new molecule.
Enfuvirtide
The first HIV entry inhibitor — a 36-amino-acid peptide that blocks viral fusion.
Enicepatide
An investigational GLP-1/GIP dual agonist reported to be advancing towards Phase 3.
Epitalon
Longevity claims built on an old, narrow and largely unreplicated body of research.
Mostly animal and lab studies — not yet shown in people
Exenatide
The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.
FLGR-242
A branded follistatin-derived protein construct marketed with muscle-growth claims. No FLGR-242-specific animal outcome study, human study or registered human trial has been identified; related evidence is not compound-specific evidence.
Mostly animal and lab studies — not yet shown in people
FOXO4-DRI
Experimental senolytic peptide with cell and mouse evidence, but no established human efficacy or safety.
Mostly animal and lab studies — not yet shown in people
Ganirelix
A GnRH antagonist used in assisted reproduction to time ovulation precisely.
Garetosmab
FDA-approved in the US for the narrow adult FOP indication; metabolic and body-composition use remains investigational.
GHK-Cu
Decent cosmetic evidence on the skin, very different question when people inject it.
GHRP-2
One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.
Mostly animal and lab studies — not yet shown in people
GHRP-6
The older sibling of GHRP-2, with historical human pharmacology but no approved indication and a notable appetite-stimulating effect.
Mostly animal and lab studies — not yet shown in people
Glucagon
The body's own counter-insulin hormone, available as approved injection and nasal rescue products — another proof that 'nasal peptide' is not shorthand for experimental.
Goserelin
A GnRH agonist delivered as a small implant under the skin of the abdomen, suppressing sex hormones in prostate and breast cancer and certain gynaecological conditions.
HDAP2
A short mitochondria-targeted research peptide that binds cardiolipin. Evidence is cell and mouse work, including 2026 optic-nerve injury data.
Mostly animal and lab studies — not yet shown in people
Histrelin
A GnRH-agonist implant approved for central precocious puberty, releasing peptide continuously for about a year per implant.
Icatibant
A synthetic decapeptide that blocks bradykinin B2 receptors, approved for acute attacks of hereditary angioedema in adults.
IGF-1 LR3
A modified long-acting IGF-1 analogue sold for bodybuilding, and not the same thing as approved IGF-1 medicine.
Mostly animal and lab studies — not yet shown in people
Ipamorelin
A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.
Mostly animal and lab studies — not yet shown in people
Kisspeptin-10
A fragment of the body's own reproductive signalling peptide, studied in human physiology research but not an approved therapy.
KPV
A three-amino-acid fragment of alpha-MSH marketed for gut healing and inflammation, with no human clinical studies identified by the FDA.
Mostly animal and lab studies — not yet shown in people
Lanreotide
A long-acting somatostatin analogue with pivotal-trial evidence for slowing tumour progression in certain neuroendocrine tumours.
Leuprolide
A GnRH agonist whose depot injections switch off sex-hormone production — used in prostate cancer, endometriosis and central precocious puberty depending on the product.
Linaclotide
A 14-amino-acid peptide swallowed as a capsule that works locally on the gut lining — approved oral proof that not every peptide is digested into uselessness.
Liraglutide
The older once-daily GLP-1 agonist, with long real-world follow-up and modest effect sizes.
Lixisenatide
A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.
LL-37
A human antimicrobial peptide studied topically for wound healing, now marketed for unrelated systemic uses.
Mostly animal and lab studies — not yet shown in people
MA-5 (Mitochonic Acid 5)
A small indole-derived molecule — not a peptide — studied in cells and mice for mitochondrial disease. No human trial evidence in our record.
Mostly animal and lab studies — not yet shown in people
Mazdutide
A GLP-1/glucagon dual agonist developed largely in Chinese trial populations.
MBX 4291
An investigational long-acting GLP-1 and GIP receptor co-agonist prodrug in Phase 1, with only preliminary small-cohort sponsor-reported data.
MBX 5765
A preclinical single-peptide construct reported to combine GLP-1, GIP and glucagon receptor activity with dual amylin and calcitonin receptor activity.
Mostly animal and lab studies — not yet shown in people
MBX 6180
A preclinical triple GLP-1, GIP and glucagon receptor agonist prodrug nominated as a development candidate in August 2026.
Mostly animal and lab studies — not yet shown in people
Melanotan II
A synthetic melanocortin peptide sold for tanning — unapproved everywhere, and routinely confused with genuinely approved melanocortin medicines.
Mostly animal and lab studies — not yet shown in people
MOTS-c
A mitochondrial-derived peptide with genuinely interesting biology and thin translational data.
Mostly animal and lab studies — not yet shown in people
Nafarelin
A GnRH agonist that has been an approved nasal-spray medicine for decades — the standing rebuttal to 'nasal peptide means research chemical'.
Octreotide
The foundational somatostatin analogue, used for acromegaly and symptom control in certain neuroendocrine tumours.
Orexin A
The natural wake-promoting neuropeptide; two small crossover studies tested intranasal dosing in narcolepsy. Not the same as approved orexin receptor drugs.
Orexin B
A distinct endogenous 28-amino-acid orexin peptide studied mainly in receptor, tissue and animal experiments; no verified human intervention was identified.
Mostly animal and lab studies — not yet shown in people
Oxytocin
The natural nonapeptide hormone of labour and lactation, long approved as an IV/IM obstetric medicine.
P021
A CNTF-derived, adamantylated tetrapeptide studied in Alzheimer's mouse models; no human trial identified. Not the same as 'P21'.
Mostly animal and lab studies — not yet shown in people
Pasireotide
A broader-spectrum somatostatin analogue approved for specific endocrine disorders including Cushing's disease.
PE-22-28
A rodent-stage antidepressant candidate being discussed online as a nootropic peptide.
Mostly animal and lab studies — not yet shown in people
PEG-MGF
A muscle-repair peptide with a compelling mechanism story and no robust human outcome evidence.
Mostly animal and lab studies — not yet shown in people
Pemvidutide
An investigational GLP-1/glucagon dual agonist now developed primarily for serious liver disease, not weight loss.
Petrelintide
A long-acting amylin analogue in Phase 2, with Phase 3 weight-management trials planned.
Phoenixin-20
A 20-amino-acid neuropeptide studied in animals and cultured cells across reproductive, gut and metabolic biology. No human trial evidence.
Mostly animal and lab studies — not yet shown in people
Pinealon
A Khavinson-series tripeptide (Glu-Asp-Arg) with cell and rodent neuroprotection studies; no independent controlled human trial identified.
Mostly animal and lab studies — not yet shown in people
Plecanatide
A 16-amino-acid oral peptide modelled on the natural gut hormone uroguanylin, approved for chronic constipation and IBS-C in adults.
PNC-27
A 32-residue chimeric peptide (p53 residues 12–26 plus a membrane-penetrating leader) studied against cancer cells in the laboratory only.
Mostly animal and lab studies — not yet shown in people
Pramlintide
A synthetic amylin analogue approved as an add-on in insulin-treated diabetes.
Prostamax
A tetrapeptide studied in cultured human lymphocytes; the cited work measured chromosome and chromatin changes, not prostate outcomes in patients.
Mostly animal and lab studies — not yet shown in people
PTD-DBM
A cell-penetrating peptide designed to block CXXC5 and boost Wnt signalling; it regrew hair in mice. No human hair-regrowth result has been shown.
Mostly animal and lab studies — not yet shown in people
Retatrutide
An investigational GIP/GLP-1/glucagon triple agonist with positive pivotal Phase 3 results and no approval anywhere.
Selank
A synthetic heptapeptide related to tuftsin, marketed online for anxiety despite no regulatory approval and almost no independent human evidence.
Mostly animal and lab studies — not yet shown in people
Semaglutide
A GLP-1 receptor agonist with one of the largest clinical trial programmes in modern metabolic medicine.
Semax
A synthetic heptapeptide derived from an ACTH fragment, registered as nasal drops in Russia and heavily marketed elsewhere as a nootropic.
Mostly animal and lab studies — not yet shown in people
Setmelanotide
An MC4R agonist approved for specific genetic obesity syndromes — precision medicine, not a general weight-loss drug.
SLU-PP-915
A small-molecule research chemical — not a peptide — that activates the ERR nuclear receptors and increased running capacity in mice. No human data.
Mostly animal and lab studies — not yet shown in people
SS-31 / Elamipretide
A mitochondria-targeting peptide with a narrow accelerated approval and a much broader set of unproven anti-ageing claims.
Survodutide
An investigational glucagon/GLP-1 dual agonist now supported by peer-reviewed Phase 3 obesity trials with and without type 2 diabetes.
TB-500 / Thymosin beta-4
A genuine biological protein with real research history, and a separate online product that is not quite the same thing.
Mostly animal and lab studies — not yet shown in people
Teduglutide
A GLP-2 analogue that helps people with short bowel syndrome reduce dependence on intravenous nutrition.
Teriparatide
A parathyroid-hormone fragment that builds bone — one of the few anabolic osteoporosis treatments.
Terlipressin
A vasopressin analogue approved intravenously for hepatorenal syndrome — with a boxed warning about serious or fatal respiratory failure.
Tesamorelin
An approved medicine for one specific indication, routinely marketed for a much broader one.
Thymosin alpha-1
A thymic immune peptide approved in dozens of countries for specific indications, but never approved in the US — and marketed far beyond any approval.
Tirzepatide
A dual GIP and GLP-1 receptor agonist with strong Phase 3 weight and glycaemic data.
Trevogrumab
An investigational myostatin-blocking antibody with controlled Phase 2 data on DXA-measured lean mass and MRI-measured thigh fat-free muscle volume alongside semaglutide, but no proven functional outcome.
Triptorelin
A long-acting GnRH agonist depot used in prostate cancer and central precocious puberty.
Vasopressin
The body's own antidiuretic nonapeptide, used intravenously in intensive care to support blood pressure in vasodilatory shock.
Vesugen
A Khavinson-series short peptide studied in cell cultures and by computer docking; no vascular benefit in people has been shown.
Mostly animal and lab studies — not yet shown in people
Vilon
A dipeptide (Lys-Glu) studied in mouse immune cells, plus one older observational Russian report in people with diabetes; no controlled efficacy trial.
Mostly animal and lab studies — not yet shown in people
VK2735
An investigational GLP-1/GIP dual agonist in Phase 3 as an injection, with an oral form behind it.
VK3019
An investigational dual amylin and calcitonin receptor agonist that entered a first-in-human Phase 1 safety study in June 2026.
VRX-0075
A preclinical single-molecule agonist reported to engage five receptors — GLP-1, GIP, glucagon, amylin and calcitonin — with no human data of any kind.
Mostly animal and lab studies — not yet shown in people
Zenagamtide
An investigational single-molecule GLP-1 and amylin receptor co-agonist now in Phase 3 obesity trials.
Ziconotide
A cone-snail-venom-derived peptide painkiller given directly into spinal fluid for severe chronic pain.
Currently discussed
This list measures conversation, not evidence
Pinealon
A short peptide discussed for cognition and 'cellular ageing'. We have not curated adequate human evidence, so there is nothing here we can grade.
P21
Discussed as a nootropic and neurogenesis peptide. Our record does not establish human studies supporting those claims.
HGH Fragment 176-191
Frequently marketed and discussed alongside AOD-9604, which has its own profile. Whether the products sold under these names are identical is not something we can state without a source — treat them as separate until sourced.
Dihexa
Taxonomy note: commonly grouped with peptides online, but it is an engineered small molecule rather than a conventional peptide. Human evidence is not established in our record.
Ecnoglutide (XW003)
A long-acting GLP-1 receptor agonist reported to have gained Chinese regulatory approvals during 2026 and not approved in the UK, US or EU. We are holding it here rather than publishing a profile until we have verified the official regulatory source.
IBIO-610 (iBio)
Preclinical only. A long-acting Activin E antibody in IND-enabling work for obesity. Sponsor-reported obese non-human primate data describe near-complete Activin E suppression through 8 weeks and, with semaglutide, more fat loss and less lean-mass loss than semaglutide alone. Animal data are not human results; first-in-human dosing is planned for H1 2027. Reviewed 3 October 2026.
IBIO-600 (iBio)
Early Phase 1. A long-acting myostatin antibody; iBio reported first dosing in June 2026 and 31 participants through single-ascending-dose cohorts by August 2026 with no safety finding precluding escalation. Phase 1 exposure is not efficacy evidence. Reviewed 3 October 2026.
HRS-1596 (Hengrui / Novo Nordisk)
Pipeline signal only. A once-weekly oral GLP-1/GIP dual agonist described as Phase 1-ready and licensed by Novo Nordisk on 29 September 2026. A licensing deal is not evidence of efficacy or safety. Reviewed 3 October 2026.
Berobenatide (PF-08653944 / MET-097i, Pfizer)
Held on the watchlist pending peer-reviewed data. An investigational ultra-long-acting injectable GLP-1 receptor agonist peptide; Pfizer reports Phase 2b VESPER results (sponsor-reported) supporting a Phase 3 programme with multiple studies advancing in 2026. A full profile awaits peer-reviewed Phase 2b publication. Reviewed 3 October 2026.
Nexus (NAD+ + MOTS-c + 5-Amino-1MQ)
Seller-defined co-lyophilised metabolic blend combining one peptide (MOTS-c), one coenzyme (NAD+) and one small-molecule NNMT inhibitor (5-Amino-1MQ). The mechanistic rationale is interesting, but no controlled human study of this three-component formulation is established in the curated record. 5-Amino-1MQ remains preclinical, while human evidence for parenteral NAD+ is sparse and does not establish anti-ageing or metabolic benefit. Track as a combination-evidence gap, not as proof of synergy. Reviewed 4 October 2026.
Commonly mentioned alongside peptides, but not peptides
These come up constantly in the same conversations and the same shops. They are not peptides, which is why you will not find them in the A–Z.
5-Amino-1MQ
A small-molecule NNMT enzyme inhibitor, not a peptide. Published evidence remains preclinical, including cell and mouse studies; no qualifying human efficacy or safety trial is established in the curated record.
SLU-PP-332
A small-molecule ERR agonist from exercise-mimetic research. Not a peptide, and preclinical.
NAD+
A coenzyme, not a peptide. Parenteral NAD+ is marketed in wellness settings, but current human evidence is sparse and does not establish clinically meaningful anti-ageing, metabolic or performance outcomes. Its appearance in peptide blends reflects a commercial grouping rather than a shared molecular class.
Two separate risks, often confused